Leukemias, lymphomas, and other hematologic cancers:
Indications for: ONTAK
Persistent or recurrent cutaneous T-cell lymphoma in which malignant cells express the CD25 component of the IL-2 receptor.
Premedicate with an antihistamine or acetaminophen prior to each infusion. Give by IV infusion over 30–60mins. 9 or 18mcg/kg per day for 5 consecutive days every 21 days for 8 cycles.
Serious infusion reactions. Capillary leak syndrome. Loss of visual acuity.
Ensure CD25 expression before starting therapy. Have resuscitative equipment available during administration. Permanently discontinue if ≥Grade 3 infusion reactions occur. Monitor for capillary leak syndrome (eg, hypotension, edema, hypoalbuminemia) and weight gain. Monitor serum albumin levels prior to each treatment course; withhold treatment if serum albumin <3g/dL. Monitor visual acuity and color vision. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective contraception during and for ≥7 days after the last dose. Nursing mothers: not recommended (during and for 7 days after the last dose).
Interleukin 2-diphtheria toxin fusion protein.
Pyrexia, fatigue, rigors, GI upset, headache, peripheral edema, cough, dyspnea, pruritus, rash, hypotension, back pain, myalgia, chest pain, tachycardia, hypoalbuminemia, asthenia, elevated transaminases.
Testing considerations: CD25 expression
Single-use vials (2mL)—6